Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T11:46:38.381Z.
Consensus retrieved: 2026-10-06T11:15:31.288Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T11:46:38.381Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
Forward PE Ratio (N/A) = Dated Quote Price ($66.47) / Consensus Forward EPS ($-1.20)
FORWARD PE RATIO
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.96B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.96B | N/A |
| Absci Corporation (ABSI)vs › | $1.95B | N/A |
| Azenta, Inc. (AZTA)vs › | $1.97B | 86.03 |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 84.11 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 25.10 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 16.65 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.35 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 59.24 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $66.47, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.20 | $-1.23 – $-1.17 | 4 | n/m |
| 2027-12-31 | $-0.02 | $-0.20 – $0.15 | 4 | n/m |
| 2028-12-31 | $1.07 | $0.78 – $1.53 | 9 | 62.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
